个体化医学在肿瘤治疗领域的应用资料.ppt

UGT1A1尿苷二磷酸葡萄糖醛酸转移酶 UGT1A1尿苷二磷酸葡萄糖醛酸转移酶 巯嘌呤6-MP 五、FDA批准有药物基因组学内容的抗肿瘤药物 Irinotecan Pathway Enteric bacterial –glucuronidase regenerates gut local tissue damage and diarrhea SN-38 : 7-ethyl-10-hydroxycamptothecin bile SN-38 FDA advisory committee: a reduction in the starting dose by at least one level [15–25%] should be considered for patients known to be homozygous for the UGT1A1*28 allele.” /bbs/topics/NEWS/2005/NEW01220.html UGT1A1 gained recognition as the first pharmacogenetic test to achieve FDA approval for use in conjunction with a specific drug (irinotecan)